Physician profile
Meshandra Williams
NPI 1366923393
$8,632.20
in general payments reported to CMS, 2019-2025
24 companies · $33.61 in 2025
The $33.61 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,006 · 2022: $2,520 · 2023: $2,551 · 2024: $1,522 · 2025: $33.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,099 · Education: $7.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,098.97 |
| Education | $7.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $2,122.92 | 2021-2024 | Fanapt, Hetlioz |
| Alkermes, INC. | $1,182.71 | 2021-2024 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $1,119.97 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $1,000.06 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $564.75 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $536.38 | 2021-2024 | Austedo Xr, Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $498.83 | 2021-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $327.20 | 2021-2023 | Invega Trinza, Invega Sustenna |
| Tempus Ai, INC | $217.52 | 2024 | |
| Jazz Pharmaceuticals INC. | $181.01 | 2022 | |
| Axsome Therapeutics, INC. | $168.73 | 2022-2023 | Sunosi |
| Avanir Pharmaceuticals, INC. | $143.50 | 2021-2022 | |
| Almatica Pharma LLC | $118.76 | 2021-2023 | Gralise |
| Lundbeck LLC | $113.55 | 2023-2024 | Rexulti |
| Corium, LLC | $88.09 | 2021-2023 | Azstarys |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $48.28 | 2021-2023 | Perseris |
| Takeda Pharmaceuticals U.S.A., INC. | $45.00 | 2023 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $32.38 | 2024 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $29.06 | 2022 | |
| Merck Sharp & Dohme LLC | $24.71 | 2022 | |
| Neos Therapeutics, LP | $20.24 | 2021 | |
| Sage Therapeutics, LLC | $19.23 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.35 | 2024 | Quviviq |
| Eisai INC. | $13.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meshandra Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.